|
English
|
正體中文
|
简体中文
|
0
|
|
???header.visitor??? :
52968720
???header.onlineuser??? :
1175
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"barlesi f"???jsp.browse.items-by-author.description???
Showing items 11-15 of 15 (2 Page(s) Totally)
<< < 1 2
View [10|25|50] records per page
| 臺大學術典藏 |
2020-05-26T09:26:24Z |
Time to response in patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) receiving alectinib in the phase ii NP28673 and NP28761 studies
|
Gadgeel S;Shaw A.T;Barlesi F;Crino L;Chih-Hsin Yang;Dingemans A.-M;Kim D.-W;Marinis F;Schulz M;Liu S;Gupta R;Smoljanovic V;Ou S.-H.I.; Gadgeel S; Shaw A.T; Barlesi F; Crino L; CHIH-HSIN YANG; Dingemans A.-M; Kim D.-W; Marinis F; Schulz M; Liu S; Gupta R; Smoljanovic V; Ou S.-H.I. |
| 臺大學術典藏 |
2020-05-26T09:26:17Z |
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer
|
Ou S.-H.I;Gadgeel S.M;Barlesi F;Chih-Hsin Yang;De Petris L;Kim D.-W;Govindan R;Dingemans A.-M;Crino L;L?na H;Popat S;Ahn J.S;Dansin E;Mitry E;M?ller B;Bordogna W;Balas B;Morcos P.N;Shaw A.T.; Ou S.-H.I; Gadgeel S.M; Barlesi F; CHIH-HSIN YANG; De Petris L; Kim D.-W; Govindan R; Dingemans A.-M; Crino L; Léna H; Popat S; Ahn J.S; Dansin E; Mitry E; Müller B; Bordogna W; Balas B; Morcos P.N; Shaw A.T. |
| 臺大學術典藏 |
2020-05-25T07:35:06Z |
Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
|
Barlesi F; Drilon A; De Braud F; Cho B.C; Ahn M.J; Siena S; Krebs M.G; Chia-Chi Lin; John T; Tan D.S.W; Seto T; Dziadziuszko R; Arkenau H.-T; Rolfo C; Wolf J; Ye C; Riehl T; Eng S; Doebele R.C. |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1�V2 trials
|
Rolfo C; de Braud F; Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs M.G; Shaw A.T; Doebele R.C.;Wilson T.R;Eng S;Johnson A;Cui N;Simmons B;Chow-Maneval E;Riehl T;Prenen H;Tan D.S.W;Chia-Chi Lin;Murakami H;Otterson G.A;Chung C.H;Chae Y.K;Li Y.-C;Ohe Y;Kim S.-W;Arkenau H.-T;Karapetis C.S;Goto K;John T;Chiu C.-H;Patel M.R;Cho B.C;Seto T;Wolf J;Ahn M.-J;Rolfo C;de Braud F;Shaw A.T;Krebs M.G;Barlesi F;Dziadziuszko R;Siena S;Drilon A; Ahn M.-J; Wolf J; Seto T; Cho B.C; Patel M.R; Chiu C.-H; John T; Goto K; Karapetis C.S; Arkenau H.-T; Kim S.-W; Ohe Y; Li Y.-C; Chae Y.K; Chung C.H; Otterson G.A; Murakami H; Chia-Chi Lin; Tan D.S.W; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson T.R; Doebele R.C. |
| 國立臺灣大學 |
2016 |
Time to response in patients with ALK plus NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies
|
Gandhi, L.; Gadgeel, S.; Shaw, A.; Barlesi, F.; Crino, L.; Yang, J. C-H.; Dingemans, A-M. C.; Kim, D-W.; de Marinis, F.; Schulz, M.; Liu, S.; Fish, S.; Kotb, A.; Ou, S-H. I.; 楊志新 |
Showing items 11-15 of 15 (2 Page(s) Totally)
<< < 1 2
View [10|25|50] records per page
|
